Newsroom
Insights from 43rd Annual J.P. Morgan Healthcare Conference
By KlickAnalytics Data Insights | January 10, 2025 08:04PM ET
Key Points
- Labcorp to participate in fireside chat at conference
- Vir Biotechnology presents Phase 1 data on T-cell engagers
- JP Morgan Chase mandates return to office for employees
- Kinder Morgan faces challenges amid slowdown in drilling activities
- Royalty Pharma to provide business update at conference
Labcorp, a leading provider of laboratory services, is set to take part in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference. This event, which will be held on January 13-16, 2025 in San Francisco, California, will provide Labcorp with a platform to showcase its innovative services and products.
During the conference, Vir Biotechnology showcased initial Phase 1 data on two T-cell engagers, VIR-5818 and VIR-5500, which target HER2-expressing solid tumors and PSMA in metastatic castration-resistant prostate cancer, respectively. This presentation highlighted the company's commitment to developing cutting-edge therapies for challenging medical conditions.
In a surprising move, JP Morgan Chase has mandated that all its employees must return to the office five days a week. While some executives acknowledge that not everyone may agree with this decision, the bank is moving ahead with its plans to end remote and hybrid working arrangements.
Kinder Morgan, a major player in midstream infrastructure, faces challenges due to a slowdown in drilling activities. Despite generating stable fee-based revenues, the company may experience disruptions in its operations as a result of these ongoing challenges.
Royalty Pharma plc, a prominent biopharmaceutical company, will be providing an update on its business performance and key accomplishments at the 43rd Annual J.P. Morgan Healthcare Conference. Founder and CEO, Pablo Legorreta, is scheduled to discuss these updates as part of a webcast presentation on January 14, 2025.
Overall, the 43rd Annual J.P. Morgan Healthcare Conference promises to be a significant event for the healthcare and biopharmaceutical industries. With companies like Labcorp, Vir Biotechnology, JP Morgan Chase, Kinder Morgan, and Royalty Pharma in attendance, the conference is set to provide valuable insights into the latest trends and developments in the market.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with